Indolent Lymphomas Other than Follicular and Marginal Zone Lymphomas

Hematology/Oncology Clinics of North America

Volumn 22, Issue 5, 2008, Pages 903-940

  Peinert, Stefan ^a   Seymour, John F ^a,b  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Indolent; Lymphoma; Management

Indexed keywords

ALEMTUZUMAB; BETA 2 MICROGLOBULIN; BORTEZOMIB; CARMUSTINE; CHLORAMBUCIL; CLADRIBINE; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; FLAVOPIRIDOL; FLUDARABINE; GRANULOCYTE COLONY STIMULATING FACTOR; LENALIDOMIDE; LUMILIXIMAB; MELPHALAN; MITOXANTRONE; NONSTEROID ANTIINFLAMMATORY AGENT; OBLIMERSEN; OFATUMUMAB; PENTOSTATIN; PREDNISONE; PURINE NUCLEOSIDE DERIVATIVE; RITUXIMAB; THALIDOMIDE; THYMIDINE KINASE;

ACUTE GRANULOCYTIC LEUKEMIA; ALLOGENEIC STEM CELL TRANSPLANTATION; AMYLOIDOSIS; ASPIRATION BIOPSY; AUTOLOGOUS STEM CELL TRANSPLANTATION; B CELL LYMPHOMA; BLOOD EXAMINATION; BLOOD VISCOSITY; BONE MARROW BIOPSY; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER RELAPSE; CANCER STAGING; CLINICAL TRIAL; CYTOGENETICS; CYTOKINE RELEASE SYNDROME; CYTOPENIA; DIFFERENTIAL DIAGNOSIS; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG FATALITY; DRUG TOLERABILITY; DRUG TOLERANCE; FATIGUE; FEVER; FLOW CYTOMETRY; FLUORESCENCE IN SITU HYBRIDIZATION; FOLLICULAR LYMPHOMA; GENETIC ANALYSIS; GRAFT VERSUS HOST REACTION; HUMAN; IMMUNE DEFICIENCY; IMMUNOPHENOTYPING; INFECTION; LEUKOCYTE COUNT; LYMPH NODE SWELLING; LYMPHADENOPATHY; LYMPHATIC LEUKEMIA; LYMPHOCYTE COUNT; LYMPHOCYTOMA; LYMPHOCYTOSIS; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; MYELODYSPLASTIC SYNDROME; NEUTROPENIA; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RASH; REVIEW; SEX DIFFERENCE; SIDE EFFECT; SMALL LYMPHOCYTIC LYMPHOMA; THROMBOCYTOPENIA; TREATMENT FAILURE; TUMOR CELL DESTRUCTION; TUMOR FLARE; WALDENSTROEM MACROGLOBULINEMIA; WHOLE BODY RADIATION;

DIAGNOSIS, DIFFERENTIAL; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; PROGNOSIS; STEM CELL TRANSPLANTATION; WALDENSTROM MACROGLOBULINEMIA;

EID: 54149115151     PISSN: 08898588     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.hoc.2008.07.005     Document Type: Review

References (265)

1. Müller-Hermelink H.K.M.E., Catovsky D., and Harris N.L. Chronic lymphocytic leukemia/small lymphocytic lymphoma. In: Jaffe E.S., Harris N.L., Stein H., et al. (Eds). World Health Organization classification of tumours pathology and genetics of tumours of haematopoietic and lymphoid tissues (2001), IARCPress, Lyon (France) 127-130
2. Morrison W., Hoppe R., Weiss L., et al. Small lymphocytic lymphoma. J Clin Oncol 7 5 (1989) 598-606
3. Evans H.L.B.J., and Youness E.L. Malignant lymphoma, small lymphocytic type: a clinicopathologic study of 84 cases with suggested criteria for intermediate lymphocytic lymphoma. Cancer 41 4 (1978) 1440-1455
4. Ahmed S., Shahid R.K., Sison C.P., et al. Orbital lymphomas: a clinicopathologic study of a rare disease. Am J Med Sci 331 2 (2006) 79-83
5. Medeiros L.J., and Harris N.L. Lymphoid infiltrates of the orbit and conjunctiva. A morphologic and immunophenotypic study of 99 cases. Am J Surg Pathol 13 6 (1989) 459-471
6. Marti G.E., Rawstron A.C., Ghia P., et al. Diagnostic criteria for monoclonal B-cell lymphocytosis. Br J Haematol 130 3 (2005) 325-332
7. Hallek M., Cheson B.D., Catovsky D., et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia (IWCLL) updating the National Cancer Institute-Working Group (NCI-WG) 1996 guidelines. Blood 111 12 (2008) 5446-5456
8. Ben-Ezra J., Burke J., Swartz W., et al. Small lymphocytic lymphoma: a clinicopathologic analysis of 268 cases. Blood 73 2 (1989) 579-587
9. Jemal A., Siegel R., Ward E., et al. Cancer statistics, 2007. CA Cancer J Clin 57 1 (2007) 43-66
10. Tsimberidou A.M., Wen S., O'Brien S., et al. Assessment of chronic lymphocytic leukemia and small lymphocytic lymphoma by absolute lymphocyte counts in 2,126 patients: 20 years of experience at the University of Texas M.D. Anderson Cancer Center. J Clin Oncol 25 29 (2007) 4648-4656
11. Rawstron A.C., Green M.J., Kuzmicki A., et al. Monoclonal B lymphocytes with the characteristics of "indolent" chronic lymphocytic leukemia are present in 3.5% of adults with normal blood counts. Blood 100 2 (2002) 635-639
12. The Non-Hodgkin's Lymphoma Classification Project. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. Blood 89 11 (1997) 3909-3918
13. National Cancer Institute sponsored study of classification of non-Hodgkin's lymphomas: summary and description of a working formulation for clinical usage. Non-Hodgkin's Lymphoma Classification Project. Cancer 49 (1982) 2112-2135
14. Cheson B., Bennett J., Grever M., et al. National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood 87 12 (1996) 4990-4997
15. Olejniczak S.H., Stewart C.C., Donohue K., et al. A quantitative exploration of surface antigen expression in common B-cell malignancies using flow cytometry. Immunol Invest 35 1 (2006) 93-114
16. Trentin L., Cabrelle A., Facco M., et al. Homeostatic chemokines drive migration of malignant B cells in patients with non-Hodgkin lymphomas. Blood 104 2 (2004) 502-508
17. Wong S., and Fulcher D. Chemokine receptor expression in B-cell lymphoproliferative disorders. Leuk Lymphoma 45 12 (2004) 2491-2496
18. Hamblin T.J., Orchard J.A., Gardiner A., et al. Immunoglobulin V genes and CD38 expression in CLL. Blood 95 7 (2000) 2455-2457
19. Jaksic O., Kardum P., Mirjana M., et al. CD38 on B-cell chronic lymphocytic leukemia cells has higher expression in lymph nodes than in peripheral blood or bone marrow. Blood 103 5 (2004) 1968-1969
20. Nagy B., Ferrer A., Larramendy M., et al. Lymphotoxin beta expression is high in chronic lymphocytic leukemia but low in small lymphocytic lymphoma: a quantitative real-time reverse transcriptase polymerase chain reaction analysis. Haematologica 88 6 (2003) 654-658
21. Horning S.J., and Rosenberg S.A. The natural history of initially untreated low-grade non-Hodgkin's lymphomas. N Engl J Med 311 23 (1984) 1471-1475
22. Carbone P.P., Kaplan H.S., Musshoff K., et al. Report of the Committee on Hodgkin's Disease Staging Classification. Cancer Res 31 11 (1971) 1860-1861
23. Pangalis G.A., Angelopoulou M.K., Vassilakopoulos T.P., et al. B-chronic lymphocytic leukemia, small lymphocytic lymphoma, and lymphoplasmacytic lymphoma, including Waldenström's macroglobulinemia: a clinical, morphologic, and biologic spectrum of similar disorders. Semin Hematol 36 2 (1999) 104-114
24. Binet J.L.A.A., Dighiero G., Chastang C., et al. A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. Cancer 48 1 (1981) 198-206
25. Rai K., Sawitsky A., Cronkite E., et al. Clinical staging of chronic lymphocytic leukemia. Blood 46 2 (1975) 219-234
26. Binet J.-L., Caligaris-Cappio F., Catovsky D., et al. Perspectives on the use of new diagnostic tools in the treatment of chronic lymphocytic leukemia. Blood 107 3 (2006) 859-861
27. Dohner H., Stilgenbauer S., Benner A., et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 343 26 (2000) 1910-1916
28. Dohner H., Fischer K., Bentz M., et al. p53 gene deletion predicts for poor survival and non-response to therapy with purine analogs in chronic B-cell leukemias. Blood 85 6 (1995) 1580-1589
29. Grever M.R., Lucas D.M., Dewald G.W., et al. Comprehensive assessment of genetic and molecular features predicting outcome in patients with chronic lymphocytic leukemia: results from the US Intergroup Phase III Trial E2997. J Clin Oncol 25 7 (2007) 799-804
30. Byrd J.C., Gribben J.G., Peterson B.L., et al. Select high-risk genetic features predict earlier progression following chemoimmunotherapy with fludarabine and rituximab in chronic lymphocytic leukemia: justification for risk-adapted therapy. J Clin Oncol 24 3 (2006) 437-443
31. Cuneo A., Rigolin G.M., Bigoni R., et al. Chronic lymphocytic leukemia with 6q- shows distinct hematological features and intermediate prognosis. Leukemia 18 3 (2004) 476-483
32. Damle R.N., Wasil T., Fais F., et al. Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood 94 6 (1999) 1840-1847
33. Hamblin T.J., Davis Z., Gardiner A., et al. Unmutated Ig VH genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood 94 6 (1999) 1848-1854
34. Orchard J.A., Ibbotson R.E., Davis Z., et al. ZAP-70 expression and prognosis in chronic lymphocytic leukaemia. Lancet 363 9403 (2004) 105-111
35. Crespo M., Bosch F., Villamor N., et al. ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia. N Engl J Med 348 18 (2003) 1764-1775
36. Ghia P., Guida G., Stella S., et al. The pattern of CD38 expression defines a distinct subset of chronic lymphocytic leukemia (CLL) patients at risk of disease progression. Blood 101 4 (2003) 1262-1269
37. Molica S., Brugiatelli M., Callea V., et al. Comparison of younger versus older B-cell chronic lymphocytic leukemia patients for clinical presentation and prognosis. A retrospective study of 53 cases. Eur J Haematol 52 4 (1994) 216-221
38. Montserrat E., Gomis F., Vallespi T., et al. Presenting features and prognosis of chronic lymphocytic leukemia in younger adults. [see comments]. Blood 78 6 (1991) 1545-1551
39. Catovsky D., Fooks J., and Richards S. Prognostic factors in chronic lymphocytic leukaemia: the importance of age, sex and response to treatment in survival. A report from the MRC CLL 1 trial. MRC Working Party on Leukaemia in Adults. Br J Haematol 72 2 (1989) 141-149
40. Jaksic B., Vitale B., Hauptmann E., et al. The roles of age and sex in the prognosis of chronic leukaemias. A study of 373 cases. Br J Cancer 64 2 (1991) 345-348
41. Hallek M., Wanders L., Ostwald M., et al. Serum beta(2)-microglobulin and serum thymidine kinase are independent predictors of progression-free survival in chronic lymphocytic leukemia and immunocytoma. Leuk Lymphoma 22 5-6 (1996) 439-447
42. Keating M.J., Kantarjian H., Freireich E.J., et al. The serum β2-microglobulin (beta2m) level is more powerful than stage in predicting response and survival in chronic lymphocytic leukemia (CLL). Blood 86 (1995) 606
43. Reinisch W., Willheim M., Hilgarth M., et al. Soluble CD23 reliably reflects disease activity in B-cell chronic lymphocytic leukemia. J Clin Oncol 12 10 (1994) 2146-2152
44. Calin G.A., Ferracin M., Cimmino A., et al. A microRNA signature associated with prognosis and progression in chronic lymphocytic leukemia. N Engl J Med 353 17 (2005) 1793-1801
45. Del Poeta G., Del Principe M.I., Luciano F., et al. High CD69 protein expression predicts a poor prognosis in B-cell chronic lymphocytic leukemia (B-CLL). ASH Annual Meeting Abstracts 110 11 (2007) 750
46. Nowakowski G.S., Hoyer J.D., Shanafelt T.D., et al. Percentage of smudge cells on blood smear predicts prognosis in chronic lymphocytic leukemia: a multicenter study. ASH Annual Meeting Abstracts 110 11 (2007) 745
47. Weisenburger D.D., Nathwani B.N., Diamond L.W., et al. Malignant lymphoma, intermediate lymphocytic type: a clinicopathologic study of 42 cases. Cancer 48 6 (1981) 1415-1425
48. Dighiero G., Maloum K., Desablens B., et al. Chlorambucil in indolent chronic lymphocytic leukemia. N Engl J Med 338 21 (1998) 1506-1514
49. Shustik C.M.R., Silver R., Sawitsky A., et al. Treatment of early chronic lymphocytic leukemia: intermittent chlorambucil versus observation. Hematol Oncol 6 1 (1988) 7-12
50. CLL Trialists' Collaborative Group. Chemotherapeutic options in chronic lymphocytic leukemia: a meta-analysis of the randomized trials. J Natl Cancer Inst 91 10 (1999) 861-868
51. Keating M.J., O'Brien S., Lerner S., et al. Long-term follow-up of patients with chronic lymphocytic leukemia (CLL) receiving fludarabine regimens as initial therapy. Blood 92 4 (1998) 1165-1171
52. Bosch F., Ferrer A., Lopez-Guillermo A., et al. Fludarabine, cyclophosphamide and mitoxantrone in the treatment of resistant or relapsed chronic lymphocytic leukaemia. Br J Haematol 119 4 (2002) 976-984
53. Keating M.J., O'Brien S., Albitar M., et al. Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. J Clin Oncol 23 18 (2005) 4079-4088
54. Wierda W., O'Brien S., Wen S., et al. Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia. J Clin Oncol 23 18 (2005) 4070-4078
55. Rawstron A.C., Kennedy B., Evans P.A.S., et al. Quantitation of minimal disease levels in chronic lymphocytic leukemia using a sensitive flow cytometric assay improves the prediction of outcome and can be used to optimize therapy. Blood 98 1 (2001) 29-35
56. Koehi U., Ying Yang L., Nowak B., et al. Effect of combined treatment with 4-hydroperoxycyclophosphamide and fludarabine on cytotoxicity and repair of damaged DNA. Acute leukemias VII: experimental approaches and novel therapies (1998), Springer-Verlag, Berlin p. 549-55
57. Catovsky D., Richards S., Matutes E., et al. Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial. Lancet 370 9583 (2007) 230-239
58. Eichhorst B.F., Busch R., Hopfinger G., et al. Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia. Blood 107 3 (2006) 885-891
59. Tsimberidou A.M., Keating M.J., Giles F.J., et al. Fludarabine and mitoxantrone for patients with chronic lymphocytic leukemia. Cancer 100 12 (2004) 2583-2591
60. Seymour J.F., Grigg A.P., Szer J., et al. Fludarabine and mitoxantrone: effective and well-tolerated salvage therapy in relapsed indolent lymphoproliferative disorders. Ann Oncol 12 10 (2001) 1455-1460
61. Mauro F., Foa R., Meloni G., et al. Fludarabine, ara-C, novantrone and dexamethasone (FAND) in previously treated chronic lymphocytic leukemia patients. Haematologica 87 9 (2002) 926-933
62. Robertson L.E., O'Brien S., Kantarjian H., et al. Fludarabine plus doxorubicin in previously treated chronic lymphocytic leukemia. Leukemia 9 6 (1995) 943-945
63. Rummel M.J., Kafer G., Pfreundschuh M., et al. Fludarabine and epirubicin in the treatment of chronic lymphocytic leukaemia: a German multicenter phase II study. Ann Oncol 10 2 (1999) 183-188
64. Weiss M.A., Maslak P.G., Jurcic J.G., et al. Pentostatin and cyclophosphamide: an effective new regimen in previously treated patients with chronic lymphocytic leukemia. J Clin Oncol 21 7 (2003) 1278-1284
65. Robak T., Blonski J.Z., Gora-Tybor J., et al. Cladribine alone and in combination with cyclophosphamide or cyclophosphamide plus mitoxantrone in the treatment of progressive chronic lymphocytic leukemia: report of a prospective, multicenter, randomized trial of the Polish Adult Leukemia Group (PALG CLL2). Blood 108 2 (2006) 473-479
66. Zhou L.J., and Tedder T.F. CD20 Workshop Panel report. In: Schlossman S.F., Boumsell L., Gilks W., et al. (Eds). Leucocyte typing v white cell differentiation antigens (1995), Oxford University Press, Oxford (UK) 511-514
67. McLaughlin P., Grillo-Lopez A., Link B., et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 16 8 (1998) 2825-2833
68. O'Brien S.M., Kantarjian H., Thomas D.A., et al. Rituximab dose-escalation trial in chronic lymphocytic leukemia. J Clin Oncol 19 8 (2001) 2165-2170
69. Hainsworth J.D., Litchy S., Barton J.H., et al. Single-agent rituximab as first-line and maintenance treatment for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma: a phase II trial of the Minnie Pearl Cancer Research Network. J Clin Oncol 21 9 (2003) 1746-1751
70. Gilleece M., and Dexter T. Effect of Campath-1H antibody on human hematopoietic progenitors in vitro. Blood 82 3 (1993) 807-812
71. Keating M.J., Flinn I., Jain V., et al. Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study. Blood 99 10 (2002) 3554-3561
72. Rai K.R., Freter C.E., Mercier R.J., et al. Alemtuzumab in previously treated chronic lymphocytic leukemia patients who also had received fludarabine. J Clin Oncol 20 18 (2002) 3891-3897
73. Ferrajoli A., O'Brien S.M., Cortes J.E., et al. Phase II study of alemtuzumab in chronic lymphoproliferative disorders. Cancer 98 4 (2003) 773-778
74. Stilgenbauer S., and Döhner H. Campath-1H-induced complete remission of chronic lymphocytic leukemia despite p53 gene mutation and resistance to chemotherapy. N Engl J Med 347 6 (2002) 452-453
75. Lozanski G., Heerema N.A., Flinn I.W., et al. Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions. Blood 103 9 (2004) 3278-3281
76. Lundin J., Kimby E., Bjorkholm M., et al. Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL). Blood 100 3 (2002) 768-773
77. Faderl S., Thomas D.A., O'Brien S., et al. Experience with alemtuzumab plus rituximab in patients with relapsed and refractory lymphoid malignancies. Blood 101 9 (2003) 3413-3415
78. Cruz R.I., Hernandez-Ilizaliturri F.J., Olejniczak S., et al. CD52 over-expression affects rituximab-associated complement-mediated cytotoxicity but not antibody-dependent cellular cytotoxicity: preclinical evidence that targeting CD52 with alemtuzumab may reverse acquired resistance to rituximab in non-Hodgkin lymphoma. Leuk Lymphoma 48 12 (2008) 2424-2436
79. Alas S., Emmanouilides C., and Bonavida B. Inhibition of interleukin 10 by rituximab results in down-regulation of Bcl-2 and sensitization of B-cell non-Hodgkin's lymphoma to apoptosis. Clin Cancer Res 7 3 (2001) 709-723
80. Chow K., Sommerlad W., Boehrer S., et al. Anti-CD20 antibody (IDEC-C2B8, rituximab) enhances efficacy of cytotoxic drugs on neoplastic lymphocytes in vitro: role of cytokines, complement, and caspases. Haematologica 87 1 (2002) 33-43
81. Di Gaetano N., Xiao Y., Erba E., et al. Synergism between fludarabine and rituximab revealed in a follicular lymphoma cell line resistant to the cytotoxic activity of either drug alone. Br J Haematol 114 4 (2001) 800-809
82. Tam C.S., and Keating M.J. Chemoimmunotherapy of chronic lymphocytic leukemia. Best Pract Res Clin Haematol 20 3 (2007) 479-498
83. Roche Press Release (Basel, Switzerland). Available at: (2007). http://www.roche.com/med-cor-2008-01-25
84. Tam C.S., Wolf M., Prince H.M., et al. Fludarabine, cyclophosphamide, and rituximab for the treatment of patients with chronic lymphocytic leukemia or indolent non-Hodgkin lymphoma. Cancer 106 11 (2006) 2412-2420
85. Keating M.J., O'Brien S., Lerner S., et al. Chemoimmunotherapy with fludarabine (F), cyclophosphamide (C), and rituximab (R) improves complete response (CR), remission duration and survival as initial therapy of chronic lymphocytic leukemia (CLL). [abstract 6565]. J Clin Oncol 22 (2004) (14S:Proceedings of the ASCO Annual Meeting)
86. Byrd J.C., Murphy T., Howard R.S., et al. Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity. J Clin Oncol 19 8 (2001) 2153-2164
87. O'Brien S., Wierda W.G., Faderl S., et al. FCR-3 as frontline therapy for patients with chronic lymphocytic leukemia (CLL). ASH Annual Meeting Abstracts 106 11 (2005) 2117
88. Faderl S., Wierda W., O'Brien S., et al. A phase II study of fludarabine (F), cyclophosphamide (C), and mitoxantrone (M) plus rituximab (R) (FCM-R) in previously untreated patients (pts) with CLL < 70 years (yrs). [abstract 6607]. J Clin Oncol 24 (2006) (18S: Proceedings of the ASCO Annual Meeting)
89. Faderl S., Wierda W., Ferrajoli A., et al. Update of experience with fludarabine, cyclophosphamide, mitoxantrone plus rituximab (FCM-R) in frontline therapy for chronic lymphocytic leukemia (CLL). ASH Annual Meeting Abstracts 110 11 (2007) 627
90. Kay N.E., Geyer S.M., Call T.G., et al. Combination chemoimmunotherapy with pentostatin, cyclophosphamide, and rituximab shows significant clinical activity with low accompanying toxicity in previously untreated B chronic lymphocytic leukemia. Blood 109 2 (2007) 405-411
91. Lamanna N., Kalaycio M., Maslak P., et al. Pentostatin, cyclophosphamide, and rituximab is an active, well-tolerated regimen for patients with previously treated chronic lymphocytic leukemia. J Clin Oncol 24 10 (2006) 1575-1581
92. Yunus F., George S., Smith J., et al. Phase II multicenter trial of pentostatin and rituximab in patients with previously treated and untreated chronic lymphocytic leukemia. [abstract 5168]. Blood 102 (2003)
93. Kennedy B., Rawstron A., Carter C., et al. Campath-1H and fludarabine in combination are highly active in refractory chronic lymphocytic leukemia. Blood 99 6 (2002) 2245-2247
94. Sayala H., Moreton P., Richard J.A., et al. Interim report of the UKCLL02 trial: a phase II study of subcutaneous alemtuzumab plus fludarabine in patients with fludarabine refractory CLL (on behalf of the NCRI CLL trials sub-group). ASH Annual Meeting Abstracts 106 11 (2005) 2120
95. Elter T., Borchmann P., Schulz H., et al. Fludarabine in combination with alemtuzumab is effective and feasible in patients with relapsed or refractory b-cell chronic lymphocytic leukemia: results of a phase II trial. J Clin Oncol 23 28 (2005) 7024-7031
96. Chanan-Khan A., Miller K.C., Takeshita K., et al. Results of a phase 1 clinical trial of thalidomide in combination with fludarabine as initial therapy for patients with treatment-requiring chronic lymphocytic leukemia (CLL). Blood 106 10 (2005) 3348-3352
97. Furman R.R., Leonard J.P., Allen S.L., et al. Thalidomide alone or in combination with fludarabine are effective treatments for patients with fludarabine-relapsed and refractory CLL. [abstract 6640]. J Clin Oncol 23 (2005) (16S:Proceedings of the ASCO Annual Meeting)
98. Giannopoulos K., Dmoszynska A., Kowal M., et al. Thalidomide alone and in combination with fludarabine exerts distinct molecular and antileukemic effects in B-cell chronic lymphocytic leukemia. ASH Annual Meeting Abstracts 110 11 (2007) 3124
99. Chanan-Khan A., Miller K.C., Musial L., et al. Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase II study. J Clin Oncol 24 34 (2006) 5343-5349
100. Chanan-Khan A., Whitworth A., Lawrence D., et al. Clinical activity of lenalidomide in relapsed or refractory chronic lymphocytic leukemia (CLL) patients: updated results of a phase II clinical trial. Leuk Lymph 48 (2007) S166
101. Ferrajoli A., Lee B.-N., Schlette E.J., et al. Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia. Blood 111 11 (2008) 5291-5297
102. Ferrajoli A., O'Brien S.M., Faderl S.H., et al. Lenalidomide induces complete and partial responses in patients with relapsed and treatment-refractory chronic lymphocytic leukemia (CLL). ASH Annual Meeting Abstracts 108 11 (2006) 305
103. Ferrajoli A., Keating M.J., Wierda W.G., et al. Lenalidomide is active in patients with relapsed/refractory chronic lymphocytic leukemia (CLL) carrying unfavorable chromosomal abnormalities. ASH Annual Meeting Abstracts 110 11 (2007) 754
104. Chanan-Khan A.A., and Cheson B.D. Lenalidomide for the treatment of B-cell malignancies. J Clin Oncol 26 9 (2008) 1544-1552
105. O'Brien S., Moore J.O., Boyd T.E., et al. Randomized phase III trial of fludarabine plus cyclophosphamide with or without oblimersen sodium (Bcl-2 antisense) in patients with relapsed or refractory chronic lymphocytic leukemia. J Clin Oncol 25 9 (2007) 1114-1120
106. Byrd J.C., O'Brien S., Flinn I., et al. Safety and efficacy results from a phase i trial of single-agent lumiliximab (anti-CD23 antibody) for chronic lymphocytic leukemia. ASH Annual Meeting Abstracts 104 11 (2004) 2503
107. Coiffier B., Tilly H., Pedersen L.M., et al. Significant correlation between survival endpoints and exposure to ofatumumab (HuMax-CD20) in chronic lymphocytic leukemia. ASH Annual Meeting Abstracts 108 11 (2006) 2842
108. Byrd J.C., Lin T.S., Dalton J.T., et al. Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia. Blood 109 2 (2007) 399-404
109. Shanafelt T.D., Geyer S.M., and Kay N.E. Prognosis at diagnosis: integrating molecular biologic insights into clinical practice for patients with CLL. Blood 103 4 (2004) 1202-1210
110. Seiler T., Döhner H., and Stilgenbauer S. Risk stratification in chronic lymphocytic leukemia. Semin Oncol 33 2 (2006) 186-194
111. Dreger P., Stilgenbauer S., Benner A., et al. The prognostic impact of autologous stem cell transplantation in patients with chronic lymphocytic leukemia: a risk-matched analysis based on the VH gene mutational status. Blood 103 7 (2004) 2850-2858
112. Pavletic Z.S., Bierman P.J., Vose J.M., et al. High incidence of relapse after autologous stem-cell transplantation for B-cell chronic lymphocytic leukemia or small lymphocytic lymphoma. Ann Oncol 9 9 (1998) 1023-1026
113. Gribben J.G., Zahrieh D., Stephans K., et al. Autologous and allogeneic stem cell transplantations for poor-risk chronic lymphocytic leukemia. Blood 106 13 (2005) 4389-4396
114. Milligan D.W., Fernandes S., Dasgupta R., et al. Results of the MRC pilot study show autografting for younger patients with chronic lymphocytic leukemia is safe and achieves a high percentage of molecular responses. Blood 105 1 (2005) 397-404
115. Rabinowe S., Soiffer R., Gribben J., et al. Autologous and allogeneic bone marrow transplantation for poor prognosis patients with B-cell chronic lymphocytic leukemia. Blood 82 4 (1993) 1366-1376
116. Khouri I., Keating M., Vriesendorp H., et al. Autologous and allogeneic bone marrow transplantation for chronic lymphocytic leukemia: preliminary results. J Clin Oncol 12 4 (1994) 748-758
117. Jantunen E., Itälä M., Siitonen T., et al. Autologous stem cell transplantation in patients with chronic lymphocytic leukaemia: the Finnish experience. Bone Marrow Transplant 37 12 (2006) 1093-1098
118. Tournilhac O., Cazin B., Lepretre S., et al. Impact of frontline fludarabine and cyclophosphamide combined treatment on peripheral blood stem cell mobilization in B-cell chronic lymphocytic leukemia. Blood 103 1 (2004) 363-365
119. Michallet M., Thiebaut A., Dreger P., et al. Peripheral blood stem cell (PBSC) mobilization and transplantation after fludarabine therapy in chronic lymphocytic leukaemia (CLL): a report of the European Blood and Marrow Transplantation (EBMT) CLL subcommittee on behalf of the EBMT Chronic Leukaemias Working Party (CLWP). Br J Haematol 108 3 (2000) 595-601
120. Morgan S.J., Seymour J.F., Grigg A., et al. Predictive factors for successful stem cell mobilization in patients with indolent lymphoproliferative disorders previously treated with fludarabine. Leukemia 18 5 (2004) 1034-1038
121. Micallef I.N., Apostolidis J., Rohatiner A.Z., et al. Factors which predict unsuccessful mobilisation of peripheral blood progenitor cells following G-CSF alone in patients with non-Hodgkin's lymphoma. Hematol J 1 6 (2000) 367-373
122. Seymour J.F., Morgan S., Prince M., et al. Ancestim (SCF) and high-dose twice-daily filgrastim (G-CSF) is superior to G-CSF alone or cyclophosphamide plus G-CSF for mobilization of peripheral blood stem cells (PBSC) in patients with indolent lymphoproliferative disorders previously treated with fludarabine; results of a historically-controlled phase-II study. ASH Annual Meeting Abstracts 108 11 (2006) 3066
123. Michallet M., Archimbaud E., Bandini G., et al. HLA-identical sibling bone marrow transplantation in younger patients with chronic lymphocytic leukemia. Ann Intern Med 124 3 (1996) 311-315
124. Khouri I., and Champlin R. Allogeneic bone marrow transplantation in chronic lymphocytic leukemia. [abstract]. Ann Intern Med 125 9 (1996) 780 -a-
125. Doney K.C., Chauncey T., and Appelbaum F.R. Seattle Bone Marrow Transplant Team. Allogeneic related donor hematopoietic stem cell transplantation for treatment of chronic lymphocytic leukemia. Bone Marrow Transplant 29 10 (2002) 817-823
126. Horowitz M., Montserrat E., Sobocinski K., et al. Haemopoietic stem cell transplantation for chronic lymphocytic leukemia. Blood Suppl I (2000) 96 [abstract 522]
127. Toze C.L., Galal A., Barnett M.J., et al. Myeloablative allografting for chronic lymphocytic leukemia: evidence for a potent graft-versus-leukemia effect associated with graft-versus-host disease. Bone Marrow Transplant 36 9 (2005) 825-830
128. Schetelig J., Thiede C., Bornhauser M., et al. Evidence of a graft-versus-leukemia effect in chronic lymphocytic leukemia after reduced-intensity conditioning and allogeneic stem-cell transplantation: the Cooperative German Transplant Study Group. J Clin Oncol 21 14 (2003) 2747-2753
129. Dreger P., Brand R., Hansz J., et al. Treatment-related mortality and graft-versus-leukemia activity after allogeneic stem cell transplantation for chronic lymphocytic leukemia using intensity-reduced conditioning. Leukemia 17 5 (2003) 841-848
130. Sorror M.L., Maris M.B., Sandmaier B.M., et al. Hematopoietic cell transplantation after nonmyeloablative conditioning for advanced chronic lymphocytic leukemia. J Clin Oncol 23 16 (2005) 3819-3829
131. Khouri I.F. Reduced-intensity regimens in allogeneic stem-cell transplantation for non-Hodgkin lymphoma and chronic lymphocytic leukemia. Hematology/The Education Program of the American Society of Hematology (2006) 390-397
132. Brown J.R., Kim H.T., Li S., et al. Predictors of improved progression-free survival after nonmyeloablative allogeneic stem cell transplantation for advanced chronic lymphocytic leukemia. Biol Blood Marrow Transplant 12 10 (2006) 1056-1064
133. Delgado J., Thomson K., Russell N., et al. Results of alemtuzumab-based reduced-intensity allogeneic transplantation for chronic lymphocytic leukemia: a British Society of Blood and Marrow Transplantation Study. Blood 107 4 (2006) 1724-1730
134. Dreger P., Brand R., Milligan D., et al. Reduced-intensity conditioning lowers treatment-related mortality of allogeneic stem cell transplantation for chronic lymphocytic leukemia: a population-matched analysis. Leukemia 19 6 (2005) 1029-1033
135. Caballero D., Garcia-Marco J.A., Martino R., et al. Allogeneic transplant with reduced intensity conditioning regimens may overcome the poor prognosis of B-cell chronic lymphocytic leukemia with unmutated immunoglobulin variable heavy-chain gene and chromosomal abnormalities (11q- and 17p-). Clin Cancer Res 11 21 (2005) 7757-7763
136. Sorror M.L., Storer B., Sandmaier B.P., et al. Long-term follow up of patients (pts) with high-risk chronic lymphocytic leukemia (CLL) given nonmyeloablative allogeneic hematopoietic cell transplantation (HCT). ASH Annual Meeting Abstracts 110 11 (2007) 1662
137. Schetelig J., van Biezen A., Caballero D., et al. Allogeneic hematopoietic cell transplantation for chronic lymphocytic leukemia (CLL) with 17p deletion: a retrospective EBMT analysis. ASH Annual Meeting Abstracts 110 11 (2007) 47
138. Shea T.C., Johnston J., Walsh W., et al. Reduced intensity allogeneic transplantation provides high disease-free and overall survival in patients (Pts) with advanced indolent NHL and CLL: CALGB 109901. ASH Annual Meeting Abstracts 110 11 (2007) 486
139. Dickinson J.D., Loberiza F., Whalen V., et al. Outcomes of hematopoietic stem cell transplantation for chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL). ASH Annual Meeting Abstracts 110 11 (2007) 3045
140. Waldenstrom J. Incipient myelomatosis or 'essential' hyperglobulinemia with fibrinogenemia: a new syndrome?. Acta Med Scand 117 (1944) 216-222
141. Harris N., Jaffe E., Stein H., et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. [see comments]. Blood 84 5 (1994) 1361-1392
142. Owen R.G., Treon S.P., and Al-Katib A. Clinicopathological definition of Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia. Semin Oncol 30 2 (2003) 110-115
143. Herrinton L., and Weiss N. Incidence of Waldenstrom's macroglobulinemia. Blood 82 10 (1993) 3148-3150
144. Groves F.D., Lois B.T., Devesa S.S., et al. Waldenström's macroglobulinemia. Cancer 82 6 (1998) 1078-1081
145. Dimopoulos M.A., Panayiotidis P., Moulopoulos L.A., et al. Waldenstrom's macroglobulinemia: clinical features, complications, and management. J Clin Oncol 18 1 (2000) 214
146. Giordano T.P., Henderson L., Landgren O., et al. Risk of non-Hodgkin lymphoma and lymphoproliferative precursor diseases in US veterans with hepatitis C virus. JAMA 297 18 (2007) 2010-2017
147. Brown A.K., Elves M.W., Gunson H.H., et al. Waldenströms macroglobulinaemia. A family study. Acta Haematol 38 3 (1967) 184-192
148. McMaster M.L., Giambarresi T., Vasquez L., et al. Cytogenetics of familial Waldenstrom's macroglobulinemia: in pursuit of an understanding of genetic predisposition. Clin Lymphoma 5 4 (2005) 230-234
149. McMaster M.L., Goldin L.R., Bai Y., et al. Genomewide linkage screen for Waldenstrom macroglobulinemia susceptibility loci in high-risk families. Am J Hum Genet 79 4 (2006) 695-701
150. Treon S.P., Hunter Z.R., Aggarwal A., et al. Characterization of familial Waldenstrom's macroglobulinemia. Ann Oncol 17 3 (2006) 488-494
151. McMaster M.L., Csako G., Giambarresi T.R., et al. Long-term evaluation of three multiple-case Waldenstrom macroglobulinemia families. Clin Cancer Res 13 17 (2007) 5063-5069
152. Linet M.S., Humphrey R.L., Mehl E.S., et al. A case-control and family study of Waldenstrom's macroglobulinemia. Leukemia 7 9 (1993) 1363-1369
153. Kyle R.A., Therneau T.M., Rajkumar S.V., et al. A long-term study of prognosis in monoclonal gammopathy of undetermined significance. N Engl J Med 346 8 (2002) 564-569
154. Dutcher T.F., and Fahey J.L. The histopathology of the macroglobulinemia of Waldenström. J Natl Cancer Inst 22 5 (1959) 887-917
155. Kucharska-Pulczynska M., Ellegaard J., and Hokland P. Analysis of leucocyte differentiation antigens in blood and bone marrow from patients with Waldenström's macroglobulinaemia. Br J Haematol 65 4 (1987) 395-399
156. Tournilhac O., Santos D.D., Xu L., et al. Mast cells in Waldenstrom's macroglobulinemia support lymphoplasmacytic cell growth through
157. Elsawa S.F., Novak A.J., Grote D.M., et al. B-lymphocyte stimulator (BLyS) stimulates immunoglobulin production and malignant B-cell growth in Waldenstrom macroglobulinemia. Blood 107 7 (2006) 2882-2888
158. Lin P., and Medeiros L.J. Lymphoplasmacytic lymphoma/Waldenstrom macroglobulinemia: an evolving concept. Adv Anat Pathol 12 5 (2005) 246-255
159. Konoplev S., Medeiros L.J., Bueso-Ramos C.E., et al. Immunophenotypic profile of lymphoplasmacytic lymphoma/Waldenström macroglobulinemia. Am J Clin Pathol 124 3 (2005) 414-420
160. Remstein E.D., Hanson C.A., and Kyle R.A. Despite apparent morphologic and immunophenotypic heterogeneity, Waldenstrom's macroglobulinemia is consistently composed of cells along a morphologic continuum of small lymphocytes, plasmacytoid lymphocytes, and plasma cells. Semin Oncol 30 2 (2005) 182-186
161. San Miguel J.F., Vidriales M.B., Ocio E., et al. Immunophenotypic analysis of Waldenstrom's macroglobulinemia. Semin Oncol 30 2 (2003) 187-195
162. Ho A.W., Hatjiharissi E., Ciccarelli B.T., et al. CD27-CD70 interactions in the pathogenesis of Waldenstrom's macroglobulinemia. Blood (2008) [epub]
163. Wagner S., Martinelli V., and Luzzatto L. Similar patterns of V kappa gene usage but different degrees of somatic mutation in hairy cell leukemia, prolymphocytic leukemia, Waldenstrom's macroglobulinemia, and myeloma. Blood 83 12 (1994) 3647-3653
164. Sahota S.S., Garand R., Bataille R., et al. VH gene analysis of clonally related IgM and IgG from human lymphoplasmacytoid B-cell tumors with chronic lymphocytic leukemia features and high serum monoclonal IgG. Blood 91 1 (1998) 238-243
165. Kriangkum J., Taylor B.J., Reiman T., et al. Origins of Waldenstrom's macroglobulinemia: does it arise from an unusual B-cell precursor?. Clin Lymphoma 5 4 (2005) 217-219
166. Kriangkum J., Taylor B.J., Treon S.P., et al. Molecular characterization of Waldenstrom's macroglobulinemia reveals frequent occurrence of two B-cell clones having distinct IgH VDJ sequences. Clin Cancer Res 13 7 (2007) 2005-2013
167. Kriangkum J., Taylor B.J., Strachan E., et al. Impaired class switch recombination (CSR) in Waldenstrom macroglobulinemia (WM) despite apparently normal CSR machinery. Blood 107 7 (2006) 2920-2927
168. Martin-Jimenez P., Garcia-Sanz R., Sarasquete M.E., et al. Functional class switch recombination may occur 'in vivo' in Waldenström macroglobulinaemia. Br J Haematol 136 1 (2007) 114-116
169. Contrafatto G. Marker chromosome of macroglobulinemia identified by G-banding. Cytogenet Cell Genet 18 6 (1977) 370-373
170. Han T., Sadamori N., Takeuchi J., et al. Clonal chromosome abnormalities in patients with Waldenstrom's and CLL-associated macroglobulinemia: significance of trisomy 12. Blood 62 3 (1983) 525-531
171. Schop RFJ, Kuehl W.M., Van Wier S.A., et al. Waldenstrom macroglobulinemia neoplastic cells lack immunoglobulin heavy chain locus translocations but have frequent 6q deletions. Blood 100 8 (2002) 2996-3001
172. Mansoor A., Medeiros L.J., Weber D.M., et al. Cytogenetic findings in lymphoplasmacytic lymphoma/Waldenström macroglobulinemia. Chromosomal abnormalities are associated with the polymorphous subtype and an aggressive clinical course. Am J Clin Pathol 116 4 (2001) 543-549
173. Jankovic G.M., Colovic M.D., Wiernik P.H., et al. Multiple karyotypic aberrations in a polymorphous variant of Waldenstrom macroglobulinemia. Cancer Genet Cytogenet 111 1 (1999) 77-80
174. Wong K.F., and So C.C. Waldenstrom macroglobulinemia with karyotypic aberrations involving both homologous 6q. Cancer Genet Cytogenet 124 2 (2001) 137-139
175. Ocio E.M., Schop R.F.J., Gonzalez B., et al. 6q deletion in Waldenström macroglobulinemia is associated with features of adverse prognosis. Br J Haematol 136 1 (2007) 80-86
176. Chang H., Qi X., Xu W., et al. Analysis of 6q deletion in Waldenstrom macroglobulinemia. Eur J Haematol 79 3 (2007) 244-247
177. Schop R.F.J., Jalal S.M., Van Wier S.A., et al. Deletions of 17p13.1 and 13q14 are uncommon in Waldenstrom macroglobulinemia clonal cells and mostly seen at the time of disease progression. Cancer Genet Cytogenet 132 1 (2002) 55-60
178. Hatzimichael E.C., Christou L., Bai M., et al. Serum levels of IL-6 and its soluble receptor (sIL-6R) in Waldenström's macroglobulinemia. Eur J Haematol 66 1 (2001) 1-6
179. Gutierrez N.C., Ocio E.M., de las Rivas J., et al. Gene expression profiling of B lymphocytes and plasma cells from Waldenstrom's macroglobulinemia: comparison with expression patterns of the same cell counterparts from chronic lymphocytic leukemia, multiple myeloma and normal individuals. Leukemia 21 3 (2007) 541-549
180. Kyle R.A., Therneau T.M., Rajkumar S.V., et al. Long-term follow-up of IgM monoclonal gammopathy of undetermined significance. Blood 102 10 (2003) 3759-3764
181. Gobbi P.G., Baldini L., Broglia C., et al. Prognostic validation of the international classification of immunoglobulin M gammopathies: a survival advantage for patients with immunoglobulin M monoclonal gammopathy of undetermined significance?. Clin Cancer Res 11 5 (2005) 1786-1790
182. Gertz M.A., and Kyle R.A. Hyperviscosity syndrome. J Intensive Care Med 10 3 (1995) 128-141
183. Dhodapkar M.V., Jacobson J.L., Gertz M.A., et al. Prognostic factors and response to fludarabine therapy in patients with Waldenstrom macroglobulinemia: results of United States intergroup trial (Southwest Oncology Group S9003). Blood 98 1 (2001) 41-48
184. Garcia-Sanz R., Montoto S., Torrequebrada A., et al. Waldenström macroglobulinaemia: presenting features and outcome in a series with 217 cases. Br J Haematol 115 3 (2001) 575-582
185. Kyle R.A., and Garton J.P. The spectrum of IgM monoclonal gammopathy in 430 cases. Mayo Clin Proc 62 (1987) 719-731
186. Zarrabi M.H., Stark R.S., and Kane P. IgM myeloma, a distinct entity in the spectrum of B-cell neoplasia. Am J Clin Pathol 75 1 (1981) 1-10
187. Takahashi K., Yamamura F., and Motoyama H. IgM myeloma-its distinction from Waldenström's macroglobulinemia. Acta Pathol Jpn 36 10 (1986) 1553-1563
188. Kondo H., and Yokoyama K. IgM myeloma: different features from multiple myeloma and macroglobulinaemia. Eur J Haematol 63 5 (1999) 366-368
189. Facon T., Brouillard M., Duhamel A., et al. Prognostic factors in Waldenstrom's macroglobulinemia: a report of 167 cases. J Clin Oncol 11 8 (1993) 1553-1558
190. Singh A., Eckardt K.U., Zimmermann A., et al. Increased plasma viscosity as a reason for inappropriate erythropoietin formation. J Clin Invest 91 1 (1993) 251-256
191. Leblond V., Tournilhac O., and Morel P. Waldenström's macroglobulinemia: prognostic factors and recent therapeutic advances. Clin Exp Med 3 4 (2004) 187-198
192. Alexanian R. Blood volume in monoclonal gammopathy. Blood 49 2 (1977) 301-307
193. MacKenzie M., and Lee T. Blood viscosity in Waldenstrom macroglobulinemia. Blood 49 4 (1977) 507-510
194. Pavy M.D., Murphy P.L., and Virella G. Paraprotein-induced hyperviscosity. A reversible cause of stroke. Postgrad Med 68 3 (1980) 109-112
195. Mueller J., Hotson J.R., and Langston J.W. Hyperviscosity-induced dementia. Neurology 33 1 (1983) 101-103
196. Barras J.P., and Graf C. Hyperviscosity in diabetic retinopathy treated with Doxium (calcium dobesilate). Vasa 9 2 (1980) 161-164
197. Vital C., Deminière C., Bourgouin B., et al. Waldenström's macroglobulinemia and peripheral neuropathy: deposition of M-component and kappa light chain in the endoneurium. Neurology 35 4 (1985) 603-606
198. Ropper A.H., and Gorson K.C. Neuropathies associated with paraproteinemia. N Engl J Med 338 22 (1998) 1601-1607
199. Dellagi K., Dupouey P., Brouet J., et al. Waldenstrom's macroglobulinemia and peripheral neuropathy: a clinical and immunologic study of 25 patients. Blood 62 2 (1983) 280-285
200. Nobile-Orazio E., Marmiroli P., Baldini L., et al. Peripheral neuropathy in macroglobulinemia: incidence and antigen-specificity of M proteins. Neurology 37 9 (1987) 1506-1514
201. Gertz M., Kyle R., and Noel P. Primary systemic amyloidosis: a rare complication of immunoglobulin M monoclonal gammopathies and Waldenstrom's macroglobulinemia. J Clin Oncol 11 5 (1993) 914-920
202. Gertz M.A., Lacy M.Q., Dispenzieri A., et al. Amyloidosis. Best Pract Res Clin Haematol 18 4 (2005) 709-727
203. Gertz M.A., and Kyle R.A. Amyloidosis with IgM monoclonal gammopathies. Semin Oncol 30 2 (2003) 325-328
204. Morel P., Monconduit M., Jacomy D., et al. Prognostic factors in Waldenstrom macroglobulinemia: a report on 232 patients with the description of a new scoring system and its validation on 253 other patients. Blood 96 3 (2000) 852-858
205. Ghobrial I.M., Fonseca R., Gertz M.A., et al. Prognostic model for disease-specific and overall mortality in newly diagnosed symptomatic patients with Waldenstrom macroglobulinaemia. Br J Haematol 133 2 (2006) 158-164
206. Kyrtsonis M.C., Vassilakopoulos T.P., Angelopoulou M.K., et al. Waldenström's macroglobulinemia: clinical course and prognostic factors in 60 patients. Experience from a single hematology unit. Ann Hematol 80 12 (2001) 722-727
207. Levy V., Morel P., Porcher R., et al. Advanced Waldenstrom's macroglobulinemia: usefulness of Morel's scoring system in establishing prognosis. Haematologica 90 2 (2005) 279-281
208. Morel P., Duhamel A., Gobbi P., et al. International prognostic scoring system (IPSS) for Waldenstrom's macroglobulinemia (WM). ASH Annual Meeting Abstracts 108 11 (2006) 127
209. Alexanian R., Weber D., Delasalle K., et al. Asymptomatic Waldenstrom's macroglobulinemia. Semin Oncol 30 2 (2003) 206-210
210. Treon S.P., Gertz M.A., Dimopoulos M., et al. Update on treatment recommendations from the Third International Workshop on Waldenstrom's macroglobulinemia. Blood 107 9 (2006) 3442-3446
211. Johnson S.A., Owen R.G., Oscier D.G., et al. Phase III study of chlorambucil versus fludarabine as initial therapy for Waldenstrom's macroglobulinemia and related disorders. Clin Lymphoma 5 4 (2005) 294-297
212. Kyle R.A., Greipp P.R., Gertz M.A., et al. Waldenström's macroglobulinaemia: a prospective study comparing daily with intermittent oral chlorambucil. Br J Haematol 108 4 (2000) 737-742
213. Petersen H.S. Erythroleukaemia in a melphalan-treated patient with primary macroglobulinaemia. Scand J Haematol 10 1 (1973) 5-11
214. Cardamone J.M., Kimmerle R.I., and Marshall E.Y. Development of acute erythroleukemia in B-cell immunoproliferative disorders after prolonged therapy with alkylating drugs. Am J Med 57 5 (1974) 836-842
215. Weide R., Heymanns J., and Köppler H. Induction of complete haematological remission after monotherapy with anti-CD20 monoclonal antibody (RITUXIMAB) in a patient with alkylating agent resistant Waldenström's macroglobulinaemia. Leuk Lymphoma 36 1-2 (1999) 203-206
216. Weide R., Heymanns J., and Koppler H. The polyneuropathy associated with Waldenström's macroglobulinaemia can be treated effectively with chemotherapy and the anti-CD20 monoclonal antibody rituximab. Br J Haematol 109 4 (2000) 838-841
217. Byrd J.C., White C.A., Link B., et al. Rituximab therapy in Waldenstrom's macroglobulinemia: preliminary evidence of clinical activity. Ann Oncol 10 12 (1999) 1525-1527
218. Treon S.P., Agus D.B., Link B., et al. CD20-directed antibody-mediated immunotherapy induces responses and facilitates hematologic recovery in patients with Waldenstrom's macroglobulinemia. J Immunother 24 3 (2001) 272-279
219. Dimopoulos M.A., Zervas C., Zomas A., et al. Treatment of Waldenstrom's macroglobulinemia with rituximab. J Clin Oncol 20 9 (2002) 2327-2333
220. Treon S.P., Emmanouilides C., Kimby E., et al. Extended rituximab therapy in Waldenstrom's macroglobulinemia. Ann Oncol 16 1 (2005) 132-138
221. Kimby E. Tolerability and safety of rituximab (MabThera(R)). Cancer Treat Rev 31 6 (2005) 456-473
222. Treon S.P., Branagan A.R., Hunter Z., et al. Paradoxical increases in serum IgM and viscosity levels following rituximab in Waldenstrom's macroglobulinemia. Ann Oncol 15 10 (2004) 1481-1483
223. Ghobrial I.M., Fonseca R., Greipp P.R., et al. Initial immunoglobulin M 'flare' after rituximab therapy in patients diagnosed with Waldenstrom macroglobulinemia. Cancer 101 11 (2004) 2593-2598
224. Hunter Z.R., Boxer M., Kahl B., et al. Phase II study of alemtuzumab in lymphoplasmacytic lymphoma: results of WMCTG trial 02-079. J Clin Oncol 24 18S (2006) [abstract 7523]
225. Owen R.G., Hillmen P., and Rawstron A.C. CD52 expression in Waldenstrom's macroglobulinemia: implications for alemtuzumab therapy and response assessment. Clin Lymphoma 5 4 (2005) 278-281
226. Foran J.M., Rohatiner A.Z., Coiffier B., et al. Multicenter phase II study of fludarabine phosphate for patients with newly diagnosed lymphoplasmacytoid lymphoma, Waldenström's macroglobulinemia, and mantle-cell lymphoma. J Clin Oncol 17 2 (1999) 546-553
227. Thalhammer-Scherrer R., Geissler K., Schwarzinger I., et al. Fludarabine therapy in Waldenström's macroglobulinemia. Ann Hematol 79 10 (2000) 556-559
228. Dimopoulos M.A., Kantarjian H., Estey E., et al. Treatment of Waldenstrom macroglobulinemia with 2-chlorodeoxyadenosine. Ann Intern Med 118 3 (1993) 195-198
229. Dimopoulos M.A., Kantarjian H., Weber D., et al. Primary therapy of Waldenström's macroglobulinemia with 2-chlorodeoxyadenosine. J Clin Oncol 12 12 (1994) 2694-2698
230. Delannoy A., Ferrant A., Martiat P., et al. 2-Chlorodeoxyadenosine therapy in Waldenstrom's macroglobulinaemia. Nouv Rev Fr Hematol 36 4 (1994) 317-320
231. Fridrik M.A., Jäger G., Baldinger C., et al. First-line treatment of Waldenström's disease with cladribine. Arbeitsgemeinschaft Medikamentöse Tumortherapie. Ann Hematol 74 1 (1997) 7-10
232. Hellmann A., Lewandowski K., Zaucha J.M., et al. Effect of a 2-hour infusion of 2-chlorodeoxyadenosine in the treatment of refractory or previously untreated Waldenström's macroglobulinemia. Eur J Haematol 63 1 (1999) 35-41
233. Weber D., Treon S.P., Emmanouilides C., et al. Uniform response criteria in Waldenstrom's macroglobulinemia: Consensus Panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia. Semin Oncol 30 2 (2003) 127-131
234. Leblond V., Lévy V., Maloisel F., et al. Multicenter, randomized comparative trial of fludarabine and the combination of cyclophosphamide-doxorubicin-prednisone in 92 patients with Waldenström macroglobulinemia in first relapse or with primary refractory disease. Blood 98 9 (2001) 2640-2644
235. Dimopoulos M.A., Weber D., Delasalle K.B., et al. Treatment of Waldenstrom's macroglobulinemia resistant to standard therapy with 2-chlorodeoxyadenosine: identification of prognostic factors. Ann Oncol 6 1 (1995) 49-52
236. Betticher D.C., Hsu Schmitz S.F., et al. Cladribine (2-CDA) given as subcutaneous bolus injections is active in pretreated Waldenström's macroglobulinaemia. Swiss Group for Clinical Cancer Research (SAKK). Br J Haematol 99 2 (1997) 358-363
237. Dimopoulos M.A., Kyle R.A., Anagnostopoulos A., et al. Diagnosis and management of Waldenstrom's macroglobulinemia. J Clin Oncol 23 7 (2005) 1564-1577
238. Seymour J., Kurzrock R., Freireich E., et al. 2-chlorodeoxyadenosine induces durable remissions and prolonged suppression of CD4+ lymphocyte counts in patients with hairy cell leukemia. Blood 83 10 (1994) 2906-2911
239. Cheson B. Infectious and immunosuppressive complications of purine analog therapy. J Clin Oncol 13 9 (1995) 2431-2448
240. Fenchel K., Bergmann L., Wijermans P., et al. Clinical experience with fludarabine and its immunosuppressive effects in pretreated chronic lymphocytic leukemias and low-grade lymphomas. Leuk Lymphoma 18 5-6 (1995) 485-492
241. Liu E.S., Burian C., Miller W.E., et al. Bolus administration of cladribine in the treatment of Waldenström macroglobulinaemia. Br J Haematol 103 3 (1998) 690-695
242. Laurencet F.M., Zulian G.B., Guetty-Alberto M., et al. Cladribine with cyclophosphamide and prednisone in the management of low-grade lymphoproliferative malignancies. Br J Cancer 79 7-8 (1999) 1215-1219
243. Van Den Neste E., Louviaux I., Michaux J.L., et al. Phase I/II study of 2-chloro-2'-deoxyadenosine with cyclophosphamide in patients with pretreated B cell chronic lymphocytic leukemia and indolent non-Hodgkin's lymphoma. Leukemia 14 6 (2000) 1136-1142
244. Tamburini J., Lévy V., Chaleteix C., et al. Fludarabine plus cyclophosphamide in Waldenström's macroglobulinemia: results in 49 patients. Leukemia 19 10 (2005) 1831-1834
245. Hensel M., Villalobos M., Kornacker M., et al. Pentostatin/cyclophosphamide with or without rituximab: an effective regimen for patients with Waldenstrom's macroglobulinemia/lymphoplasmacytic lymphoma. Clin Lymphoma Myeloma 6 2 (2005) 131-135
246. Tam C.S., Wolf M.M., Westerman D., et al. Fludarabine combination therapy is highly effective in first-line and salvage treatment of patients with Waldenström's macroglobulinemia. Clin Lymphoma Myeloma 6 2 (2005) 136-139
247. Peinert S, Tam CS, Prince HM, et al. Fludarabine based combinations are highly effective and safe as first-line or salvage treatment for patients with Waldenström's macroglobulinemia. Accepted for publication.
248. Tedeschi A., Miqueleiz S., Ricci F., et al. Fludarabine, cyclophosphamide and rituximab in Waldenstrom's macroglobulinemia: an effective regimen requiring a new category of response criteria and a delayed assessment of results. ASH Annual Meeting Abstracts 110 11 (2007) 1290
249. Vargaftig J., Pegourie-Bandelier B., Mahe B., et al. Fludarabine plus cyclophosphamide and rituximab (RFC) in Waldenstrom's macroglobulinemia (WM): results in 21 patients (pts). ASH Annual Meeting Abstracts 108 11 (2006) 4727
250. Treon S.P., Hunter Z., and Barnagan A.R. CHOP plus rituximab therapy in Waldenstrom's macroglobulinemia. Clin Lymphoma 5 4 (2005) 273-277
251. Abonour R., Zhang L.A., Rajkumar V., et al. Phase II pilot study of rituximab + CHOP in patients with newly diagnosed Waldenstrom's macroglobulinemia, an Eastern Cooperative Oncology Group Trial (Study E1A02). ASH Annual Meeting Abstracts 110 11 (2007) 3616
252. Dhedin N., Tabrizi R., Bulabois P.E., et al. Hematopoietic stem cell transplantation (HSCT) in Waldenstrom macroglobulinemia (WM), update of the French experience in 54 cases. ASH Annual Meeting Abstracts 110 11 (2007) 3015
253. Kyriakou C., Canals C., Sureda A., et al. The role of autologous stem cell transplantation (ASCT) in patients with advanced Waldenstrom's macroglobulinemia. ASH Annual Meeting Abstracts 110 11 (2007) 941
254. Kyriakou C., Canals C., Sureda A., et al. Allogeneic stem cell transplantation (allo-SCT) in the management of advanced Waldenstrom's macroglobulinemia (WM). ASH Annual Meeting Abstracts 110 11 (2007) 619
255. Dimopoulos M., Anagnostopoulos A., Kyrtsonis M., et al. Treatment of relapsed or refractory Waldenstrom's macroglobulinemia with bortezomib. Haematologica 90 12 (2005) 1655-1658
256. Treon S.P., Hunter Z.R., Matous J., et al. Multicenter clinical trial of bortezomib in relapsed/refractory Waldenstrom's macroglobulinemia: results of WMCTG Trial 03-248. Clin Cancer Res 13 11 (2007) 3320-3325
257. Ghobrial I.M., Padmanabhan S., Badros A., et al. Phase II trial of combination of bortezomib and rituximab in relapsed and/or refractory Waldenstrom macroglobulinemia: preliminary results. ASH Annual Meeting Abstracts 110 11 (2007) 4494
258. Treon S.P., Soumerai J.D., Patterson C.J., et al. Bortezomib, dexamethasone and rituximab (BDR) is a highly active regimen in the primary therapy of Waldenstrom's macroglobulinemia: planned interim results of WMCTG clinical trial 05-180. ASH Annual Meeting Abstracts 108 11 (2006) 2765
259. Dimopoulos M.A., Zomas A., Viniou N.A., et al. Treatment of Waldenstrom's macroglobulinemia with thalidomide. J Clin Oncol 19 16 (2001) 3596-3601
260. Dimopoulos M.A., Tsatalas C., Zomas A., et al. Treatment of Waldenstrom's macroglobulinemia with single-agent thalidomide or with the combination of clarithromycin, thalidomide and dexamethasone. Semin Oncol 30 2 (2003) 265-269
261. Kaplan A.A. Therapeutic apheresis for the renal complications of multiple myeloma and the dysglobulinemias. Ther Apher 5 3 (2001) 171-175
262. Buskard N.A., Galton D.A., Goldman J.M., et al. Plasma exchange in the long-term management of Waldenström's macroglobulinemia. Can Med Assoc J 117 2 (1977) 135-137
263. Orengo I.F., Kettler A.H., Bruce S., et al. Cutaneous Waldenström's macroglobulinemia. A report of a case successfully treated with radiotherapy. Cancer 60 6 (1987) 1341-1345
264. Allbritton J.I., and Horn T.D. Cutaneous lymphoplasmacytic lymphoma. J Am Acad Dermatol 38 5 Pt 2 (1998) 820-824
265. Malik K.J., Berntson D.G., and Harrison A.R. Lymphoplasmacytic lymphoma isolated to an extraocular muscle. Ophthal Plast Reconstr Surg 22 5 (2006) 400-401